Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.21 |
---|---|
High | 8.90 |
Low | 7.91 |
Bid | 8.40 |
Offer | 9.19 |
Previous close | 7.87 |
Average volume | 656.28k |
---|---|
Shares outstanding | 57.27m |
Free float | 55.16m |
P/E (TTM) | -- |
Market cap | 450.69m USD |
EPS (TTM) | -2.19 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Olema Oncology to Participate in Upcoming Investor Conferences
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
- Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
- Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Olema Oncology to Participate in Upcoming Investor Conferences in June
- Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
- Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
More ▼